SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (4027)4/14/1998 2:53:00 PM
From: Brian Malloy  Read Replies (1) of 6136
 
I think a few analysts will be caught a little flat footed for many of the reasons that you point out in your post. They seem not to understand what protease inhibitors do, that they are given in combination for therapy or the emergence of resistance. The more protease inhibitors you have in the doctors armamentum of choices, the better for the patient and for that matter the drug companies. It is synergistic.

It appears that there is a good possibility of an earnings surprise. AGPH looks on paper like it might come in anywhere between .39 and .43 for the quarter. The closer we are to the .43 figure or above the better our chance of getting a breakout on Wednesday.

Good Luck to all,
Brian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News